Violet is a therapeutics company leveraging the C-to-C Engine, a proprietary platform for the identification of cell-to-cell interactions with a specific focus on diseases of the central nervous system (CNS).

Our lead program is a small molecule inhibitor of EphB3, the first target identified by the C-to-C Engine. EphB3 is a receptor tyrosine kinase that mediates microglia-astrocyte interactions driving glial dysfunction in neurodegenerative disease.